Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.

Abstract

Gemcitabine is an active new agent in the treatment of NSCLC. This schedule was associated with little alopecia or myelosuppression. Gemcitabine warrants further investigation in other malignancies and in combination with other agents.